drugset / Trial / NCT03899987
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
Phase 2
Active not recruiting
12 enrolled
Roswell Park Cancer Institute
AIM ImmunoTech Inc. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This phase II trial studies how well enteric-coated (EC) aspirin and rintatolimod with or without interferon-alpha 2b work in treating patients with prostate cancer before surgery. EC Aspirin may help to keep the prostate cancer from coming back. Rintatolimod may stimulate the immune system and interfere with the ability of tumor cells to grow and spread. Interferon-alpha 2b may improve the body's natural response to infections and may slow tumor growth. It is not yet known how well rintatolimod, EC aspirin, and interferon-alpha 2b work in treating patients with prostate cancer undergoing surgery.
Timeline
- Start
- 2019-11-29
- Primary completion
- 2027-04-30
- Completion
- 2027-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | — | Oral |
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | — | Intravenous |
| Subject | Rintatolimod | Oligonucleotide (other) | — | Intravenous |